Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference in Boston

QUÉBEC CITY, Aug. 2, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will make a corporate presentation at the upcoming Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 9, 2011, at 2 p.m. (Eastern Time) in the London Room of the Intercontinental Boston Hotel, in Boston.

A live webcast of the presentation will be available on Aeterna Zentaris' website at www.aezsinc.com, in the Newsroom section. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.